About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Cdkn2a
cyclin dependent kinase inhibitor 2A
MGI:104738
129 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Atrtm2Bal/Atrtm2Bal
Cdkn2atm2Brn/Cdkn2atm2Brn
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		abnormal nervous system morphology J:181920
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(Vil1-cre)20Syr/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2 		cachexia J:204354
hunched posture J:204354
increased intestinal adenoma incidence J:204354
Braftm1.1Brd/Braf+
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Tg(Vil1-cre)997Gum/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL 		increased carcinoma incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL 		increased incidence of tumors by chemical induction J:147434
increased melanoma incidence J:147434
increased skin tumor incidence J:147434
Braftm1Mmcm/Braf+
Cdkn2atm4Rdp/Cdkn2atm4Rdp
involves: 129P2/OlaHsd 		increased lung tumor incidence J:121715
Cav1tm1Mls/Cav1tm1Mls
Cdkn2atm1Rdp/Cdkn2atm1Rdp
involves: 129/Sv * C57BL/6 * SJL 		abnormal branching of the mammary ductal tree J:90334
abnormal cell cycle J:90334
abnormal mammary gland duct morphology J:90334
increased fibroblast proliferation J:90334
mammary gland duct hyperplasia J:90334
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Cdkn2atm1Rdp/Cdkn2atm1Rdp
involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL 		abnormal cell physiology J:72780
abnormal keratinocyte physiology J:72780
abnormal skin development J:72780
abnormal skin physiology J:72780
delayed cellular replicative senescence J:72780
increased keratinocyte proliferation J:72780
increased squamous cell carcinoma incidence J:72780
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
Tgfb2tm1Doe/Tgfb2+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 		primary vitreous hyperplasia J:149526
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
Tgfb2tm1Doe/Tgfb2tm1Doe
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 		primary vitreous hyperplasia J:149526
Cdkn2atm1.1Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		increased mesothelioma incidence J:132943
increased metastatic potential J:132943
increased rhabdomyosarcoma incidence J:132943
increased tumor incidence J:132943
pleural effusion J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Cdkn2btm2Brn/Cdkn2btm2Brn
involves: 129P2/OlaHsd * FVB/N 		increased incidence of tumors by chemical induction J:125189
increased skin tumor incidence J:125189
normal neoplasm J:125189
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
involves: 129P2/OlaHsd * FVB/N 		abnormal meninges morphology J:131179
hydrocephaly J:131179
increased liver tumor incidence J:131179
increased meningioma incidence J:131179
increased osteoma incidence J:131179
osseous metaplasia J:131179
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
involves: 129P2/OlaHsd * FVB/N 		increased meningioma incidence J:173718
normal mortality/aging J:173718
normal neoplasm J:173718
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		increased mesothelioma incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased Schwannoma incidence J:132943
increased tumor incidence J:132943
premature death J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Pknox1tm1Fbla/Pknox1tm1Fbla
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 		abnormal pluripotent precursor cell morphology J:165811
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Pknox1tm1Fbla/Pknox1tm1Fbla
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		preweaning lethality, complete penetrance J:165811
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd 		increased mesothelioma incidence J:132943
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N 		ascites J:198619
distended abdomen J:198619
increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
jaundice J:198619
premature death J:198619
weight loss J:198619
Cdkn2atm1Cjs/Cdkn2a+
Tgfb2tm1Doe/Tgfb2tm1Doe
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 		primary vitreous hyperplasia J:149526
Cdkn2atm1Cjs/Cdkn2a+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * FVB/N * SJL 		decreased tumor incidence J:120284
premature death J:120284
Cdkn2atm1Cjs/Cdkn2a+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
involves: 129X1/SvJ * FVB 		increased rhabdomyosarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2a+
Kat5tm1Jwl/Kat5+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		decreased tumor latency J:125164
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev
involves: 129X1/SvJ * C57BL/6 * FVB/N 		increased cell proliferation J:142030
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Nop53tm2.1Asuz/Nop53tm2.1Asuz
Tg(Lck-cre)#Jxm/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA 		decreased thymocyte number J:241062
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
involves: 129S2/SvPas * 129X1/SvJ * FVB 		increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7tm1Pgr
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
involves: 129S2/SvPas * 129X1/SvJ * FVB 		increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pdgfrbtm1Sor/Pdgfrbtm1Sor
involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 		abnormal vitreous body morphology J:101016
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)68Dla/0
involves: 129X1/SvJ * FVB/N 		increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
increased tumor incidence J:99991
premature death J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)76Dla/0
involves: 129X1/SvJ * FVB/N 		increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
increased tumor incidence J:99991
premature death J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tacstd2tm1Lsm/Tacstd2tm1Lsm
involves: 129X1/SvJ * C57BL/6 		abnormal skin development J:182647
enhanced wound healing J:182647
increased carcinoma incidence J:182647
increased keratinocyte migration J:182647
increased keratinocyte proliferation J:182647
increased skin squamous cell carcinoma incidence J:182647
increased spindle cell carcinoma incidence J:182647
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
involves: 129X1/SvJ * FVB 		increased rhabdomyosarcoma incidence J:237183
skeletal muscle hyperplasia J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(GFAP-TVA)5Hev/0
involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
premature death J:125535
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(NES-TVA)J12Ech/0
involves: 129X1/SvJ * C57BL/6 * FVB/N 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
premature death J:125535
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd 		abnormal tumor incidence J:93298
increased carcinoma incidence J:93298
increased tumor growth/size J:93298
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 		abnormal eye morphology J:75215
abnormal lens capsule morphology J:75215
persistent hyperplastic primary vitreous J:75215
Cdkn2atm1Nesh/Cdkn2atm1Nesh
X/Tg(Tyr-HRAS)60Lc
involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB 		increased melanoma incidence J:85075
Cdkn2atm1Rdp/Cdkn2a+
Nf1tm1Tyj/Nf1+
involves: 129S2/SvPas * 129S6/SvEvTac 		increased neurofibrosarcoma incidence J:131914
Cdkn2atm1Rdp/Cdkn2a+
Lig4tm1Fwa/Lig4tm1Fwa
involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL 		decreased cell proliferation J:63078
increased cellular sensitivity to ionizing radiation J:63078
increased neuron apoptosis J:63078
prenatal lethality, complete penetrance J:63078
Cdkn2atm1Rdp/Cdkn2a+
Terctm1Rdp/Terctm1Rdp
involves: 129/Sv * C57BL/6J * SJL 		increased lymphoma incidence J:120065
increased sarcoma incidence J:120065
increased tumor incidence J:120065
Cdkn2atm1Rdp/Cdkn2a+
Tg(NES-TVA)J12Ech/0
involves: 129 * C57BL/6 * FVB/N * SJL 		increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2a+
Tg(S100b-v-erbB)4496Waw/0
involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL 		increased glioma incidence J:82649
Cdkn2atm1Rdp/Cdkn2a+
Tg(Tyr-NRAS*Q61K)1Bee/?
involves: 129/Sv * C57BL/6 * DBA/2 * SJL 		increased cutaneous melanoma incidence J:98545
Cdkn2atm1Rdp/Cdkn2a+
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL 		decreased tumor-free survival time J:197052
increased metastatic potential J:197052
increased pancreas tumor incidence J:197052
increased pancreatic ductal adenocarcinoma incidence J:197052
Cdkn2atm1Rdp/Cdkn2a+
X/Tg(Tyr-HRAS)60Lc
involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL 		cataract J:140820
increased incidence of tumors by UV-induction J:140820
increased intraocular melanoma incidence J:140820
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL 		increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Dicer1tm1Snj/Dicer1tm1Snj
involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * SJL 		increased cell proliferation J:139257
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Dicer1tm1Snj/Dicer1tm1Snj
involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * SJL 		normal cellular phenotype J:139257
Cdkn2atm1Rdp/Cdkn2atm1Rdp
E4f1tm1Pisc/E4f1tm1.1Llca
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		abnormal keratinocyte physiology J:167157
epidermal hyperplasia J:167157
hyperkeratosis J:167157
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Fbxw11tm1Nakay/Fbxw11tm1Nakay
B6.Cg-Cdkn2atm1Rdp Fbxw11tm1Nakay 		embryonic growth arrest J:228222
embryonic growth retardation J:228222
embryonic lethality during organogenesis, complete penetrance J:228222
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
involves: 129 * C57BL/6J * SJL 		increased fibrosarcoma incidence J:146617
increased sarcoma incidence J:146617
intestinal fibrosis J:146617
skeletal muscle interstitial fibrosis J:146617
skin fibrosis J:146617
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL 		increased melanoma incidence J:221902
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Krastm4Tyj/Kras+
involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL 		increased lung adenocarcinoma incidence J:124682
premature death J:124682
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Lig4tm1Fwa/Lig4tm1Fwa
involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL 		decreased cell proliferation J:63078
prenatal lethality, complete penetrance J:63078
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Mxi1tm1Rdp/Mxi1tm1Rdp
involves: 129/Sv * C57BL/6J * SJL 		increased tumor incidence J:48236
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Nf1tm1Tyj/Nf1+
involves: 129S2/SvPas * 129S6/SvEvTac 		increased leukemia incidence J:131914
increased lymphoma incidence J:131914
increased neurofibrosarcoma incidence J:131914
normal nervous system phenotype J:131914
premature death J:131914
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL 		increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Rnf2tm1Mvi/Rnf2tm1Mvi
Tg(Mx1-cre)1Cgn/0
involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL 		abnormal common myeloid progenitor cell morphology J:130397
enlarged liver J:130397
enlarged spleen J:130397
normal hematopoietic system phenotype J:130397
increased lymphoma incidence J:130397
premature death J:130397
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Rnf2tm1Mvl/Rnf2tm1Mvl
involves: 129P2/Ola * 129/Sv * C57BL/6J * FVB/N * SJL 		abnormal forebrain development J:82399
abnormal somite development J:82399
embryonic growth arrest J:82399
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Sox10tm1Weg/Sox10+
Tg(Tyr-NRAS*Q61K)1Bee/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * SJL 		normal neoplasm J:193443
normal pigmentation phenotype J:193443
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Terctm1Rdp/Terctm1Rdp
involves: 129/Sv * C57BL/6J * SJL 		abnormal intestine morphology J:120065
abnormal telomere length J:120065
decreased body size J:120065
decreased body weight J:120065
decreased cell proliferation J:120065
increased lymphoma incidence J:120065
increased male germ cell apoptosis J:120065
increased sarcoma incidence J:120065
increased tumor incidence J:120065
kyphosis J:120065
premature aging J:120065
testicular atrophy J:120065
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)5Hev/0
involves: 129/Sv * BALB/c * C57BL/6 * FVB/N * SJL 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
premature death J:125535
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)10Ech/0
involves: 129 * BALB/c * C57BL/6 * FVB/N * SJL 		hydrocephaly J:52161
increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Mt1-Hgf)19Lmb/0
involves: 129/Sv * C57BL/6J * FVB/N * SJL 		abnormal myogenesis J:79704
increased melanoma incidence J:79704
increased rhabdomyosarcoma incidence J:79704
increased satellite cell number J:79704
increased tumor incidence J:79704
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0
involves: 129 * C57BL/6 * FVB/N * SJL 		hydrocephaly J:52161
increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0
involves: 129/Sv * C57BL/6 * FVB/N * SJL 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:153220
premature death J:125535, J:153220
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(S100b-v-erbB)4496Waw/0
involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL 		decreased tumor latency J:82649
increased glioma incidence J:82649
increased oligodendroglioma incidence J:82649
premature death J:82649
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
involves: 129 * C57BL/6J * FVB/N * SJL 		increased lung adenocarcinoma incidence J:73468, J:166963
increased lung tumor incidence J:73468
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-rtTA)37Lc/0
involves: 129/Sv * C57BL/6J * SJL 		abnormal prostate gland physiology J:144358
increased prostate gland adenocarcinoma incidence J:144358
premature death J:144358
prostate gland hyperplasia J:144358
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-Nras*Q61K)#Lc/0
Tg(Tyr-rtTA)37Lc/0
FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc 		increased cutaneous melanoma incidence J:238049
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)470Fgh/0
involves: 129/Sv * C57BL/6J * CBA * SJL 		hydrocephaly J:151455
increased melanoma incidence J:151455
paralysis J:151455
premature death J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)476Fgh/0
involves: 129/Sv * C57BL/6J * CBA * SJL 		increased melanoma incidence J:151455
premature death J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
X/Tg(Tyr-HRAS)60Lc
involves: 129/Sv * C57BL/6J * CBA/J * SJL 		decreased tumor growth/size J:164588
decreased tumor-free survival time J:164588
increased melanoma incidence J:164588
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/?
involves: 129/Sv * C57BL/6 * DBA/2 * SJL 		enlarged lymph nodes J:98545
increased cutaneous melanoma incidence J:98545
increased metastatic potential J:98545
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/0
involves: 129/Sv * C57BL/6J * DBA/2 * SJL 		hyperpigmentation J:193443
increased cutaneous melanoma incidence J:193443
skin lesions J:193443
Cdkn2atm1Sxs/Cdkn2a+
Tgfb2tm1Doe/Tgfb2tm1Doe
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 		primary vitreous hyperplasia J:149526
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
Hdac2tm1.2Rdp/Hdac2tm1.2Rdp
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal mitosis J:197818
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB 		abnormal melanocyte morphology J:164588
hyperpigmentation J:164588
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Ezh2tm1.1Nesh/Ezh2+
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB 		increased melanoma incidence J:239472
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB 		abnormal melanocyte morphology J:164588
hyperpigmentation J:164588
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
increased tumor growth/size J:164588
premature death J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj 		hyperpigmentation J:220627
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S4/SvJae * C57BL/6 * FVB 		abnormal melanocyte morphology J:164588
hyperpigmentation J:164588
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB 		increased melanoma incidence J:239472
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp 		increased cutaneous melanoma incidence J:220627
increased metastatic potential J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Tg(Tyr-cre/ERT2)13Bos/0
B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh 		abnormal melanocyte proliferation J:220627
hyperpigmentation J:220627
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)13Bos/0
B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1Tyj Cdkn2atm2.1Nesh 		abnormal melanocyte proliferation J:220627
hyperpigmentation J:220627
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB 		abnormal melanocyte morphology J:164588
hyperpigmentation J:164588
increased melanoma incidence J:164588
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N 		increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N 		increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N 		increased lung adenocarcinoma incidence J:124682
increased metastatic potential J:124682
premature death J:124682
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N 		increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N 		increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N 		increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N 		ascites J:198619
distended abdomen J:198619
increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
jaundice J:198619
premature death J:198619
weight loss J:198619
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+
involves: 129S2/SvPas * 129S6/SvEvTac 		increased lymphoma incidence J:131914
normal neoplasm J:131914
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(GFAP-TVA)5Hev/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
premature death J:125535
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(NES-TVA)J12Ech/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N 		increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
premature death J:125535
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc
involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB 		increased melanoma incidence J:85075
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N 		increased lung tumor incidence J:124682
lung hemorrhage J:124682
premature death J:124682
Cdkn2atm2Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
involves: 129P2/OlaHsd 		enlarged liver J:132943
increased leukemia incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
premature death J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Ezh1tm1Sgon/Ezh1tm1Sgon
Tg(VAV1-cre)1Graf/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 		normal hematopoietic system phenotype J:193722
Cdkn2atm2Brn/Cdkn2atm2Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N 		abnormal pancreas development J:195229
increased cell proliferation J:195229
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+
involves: 129P2/OlaHsd 		increased leukemia incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
premature death J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2tm2Gth
involves: 129P2/OlaHsd 		enlarged liver J:132943
increased leukemia incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
premature death J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
involves: C57BL/6 * FVB/N 		increased classified tumor incidence J:107175
increased cutaneous melanoma incidence J:107175
increased neurofibrosarcoma incidence J:107175
Cdkn2atm3(cre)Cjs/Cdkn2atm4Cjs
Pdgfrbtm11Sor/Pdgfrbtm11Sor
involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6 		normal vision/eye phenotype J:147752
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N 		increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129 * FVB/N 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
increased stomach tumor incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * C57BL/6 * CBA * FVB/N 		normal neoplasm J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae 		increased lung adenocarcinoma incidence J:195492
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6 		increased sarcoma incidence J:125101
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA 		increased pancreatic ductal adenocarcinoma incidence J:187012
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N 		decreased tumor-free survival time J:87196, J:116130
increased malignant tumor incidence J:87196
increased metastatic potential J:87196, J:108298
increased pancreas tumor incidence J:87196, J:108298
increased pancreatic ductal adenocarcinoma incidence J:87196, J:108298, J:116130
increased pancreatic intraepithelial neoplasia incidence J:87196
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129 * FVB/N 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N 		decreased tumor-free survival time J:116130
increased pancreatic ductal adenocarcinoma incidence J:116130
increased stomach tumor incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		abnormal metabolism J:151781
increased pancreas tumor incidence J:151781
pancreas cyst J:151781
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		increased rhabdomyosarcoma incidence J:93444
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Nf1tm1Par/Nf1tm1Par
involves: 129S1/Sv * 129X1/SvJ 		increased neurofibrosarcoma incidence J:234760
increased rhabdomyosarcoma incidence J:234760
increased sarcoma incidence J:234760
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory